| Company/Division name | GSK |
| Parent company | GSK |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 2024 |
| Year reshoring implemented or to be implemented: | 2027 |
| Capital investment ($): | 800 |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | Marietta |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Drug Products |
| What non-domestic negative factors made offshoring less attractive? | Green considerations |
| What domestic positive factors made reshoring more attractive? | Impact on domestic economy, Infrastructure, Proximity to customers/market, Skilled workforce availability/training |
